Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
|Videos|April 19, 2011
Ted Okon on the Challenges of the VBID
Author(s)Ted Okon
Ted Okon the Executive Director of the Community Oncology Alliance (COA) Discusses the Challenges of the Value-Based Insurance Design
Advertisement
Ted Okon the Executive Director of the Community Oncology Alliance (COA) Discusses the Challenges of the Value-Based Insurance Design
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Average-Risk Adults
2
Sonesitatug Vedotin Improves Overall Survival in Second- and Later-Line CLDN18.2-Positive Gastric/GEJ Cancer
3
Volume, Biomarkers, and Cost Realities Guide ARPI Sequencing in Advanced Prostate Cancer
4
Updated Safusidenib Data Show Durable Responses in Grade 2 IDH1-Mutant Glioma
5